Knowledge Management System of Hefei Institute of Physical Science,CAS
Pyrotinib as neoadjuvant therapy for HER2+breast cancer: A multicenter, randomized, controlled, phase II trial. | |
Ding, Xiaowen; Mo, Wenju; Xie, Xiaohong; Wang, Ouchen; Ding, Yuqin; Zhao, Shuai; He, Xiangming; Feng, Weiliang; Zou, Dehong; Yang, Hongjian | |
2021-05-20 | |
发表期刊 | JOURNAL OF CLINICAL ONCOLOGY |
ISSN | 0732-183X |
DOI | 10.1200/JCO.2021.39.15_suppl.574 |
收录类别 | SCI |
语种 | 英语 |
资助项目 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
项目资助者 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
WOS研究方向 | Oncology |
WOS类目 | Oncology |
WOS记录号 | WOS:000708120600084 |
出版者 | LIPPINCOTT WILLIAMS & WILKINS |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://ir.hfcas.ac.cn:8080/handle/334002/126495 |
专题 | 中国科学院合肥物质科学研究院 |
作者单位 | 1.Univ Chinese Acad Sci, Chinese Acad Sci, Inst Canc & Basic Med ICBM, Canc Hosp,Zhejiang Canc Hosp, Hangzhou, Peoples R China 2.Zhejiang Hosp Tradit Chinese Med, Hangzhou, Peoples R China 3.Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Peoples R China |
推荐引用方式 GB/T 7714 | Ding, Xiaowen,Mo, Wenju,Xie, Xiaohong,et al. Pyrotinib as neoadjuvant therapy for HER2+breast cancer: A multicenter, randomized, controlled, phase II trial.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39. |
APA | Ding, Xiaowen.,Mo, Wenju.,Xie, Xiaohong.,Wang, Ouchen.,Ding, Yuqin.,...&Yang, Hongjian.(2021).Pyrotinib as neoadjuvant therapy for HER2+breast cancer: A multicenter, randomized, controlled, phase II trial..JOURNAL OF CLINICAL ONCOLOGY,39. |
MLA | Ding, Xiaowen,et al."Pyrotinib as neoadjuvant therapy for HER2+breast cancer: A multicenter, randomized, controlled, phase II trial.".JOURNAL OF CLINICAL ONCOLOGY 39(2021). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论